NAD+: Research Overview

The short version

NAD+ stands for nicotinamide adenine dinucleotide. It is not a peptide — it is a coenzyme, a small molecule present in every living cell. It plays two distinct roles: it shuttles electrons through the biochemical reactions that generate ATP (energy), and it acts as a consumed substrate for signaling enzymes — most notably the sirtuins, which regulate gene expression and stress response, and the PARPs, which repair damaged DNA.

NAD+ declines with age. The decline appears partly driven by rising levels of an enzyme called CD38, which consumes NAD+ more aggressively as we grow older ^[16]. The working hypothesis in aging research is that this decline contributes to the metabolic dysfunction and reduced stress resilience that characterize cellular aging, and that restoring NAD+ levels — most practically by supplementing with precursors like NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside) — might slow some of these effects.

The human evidence is real but measured. Precursor supplementation reliably raises blood NAD+ ^[14][17]. Whether that translates to meaningful clinical outcomes — longer lives, fewer diseases, better functional aging — is still an open question as of a 2025 Nature Metabolism review ^[13]. This page lays out what is established, what is promising but unproven, and where the honest uncertainty lies.

What it is

NAD+ is a dinucleotide: two nucleotides (nicotinamide mononucleotide and adenosine monophosphate) joined by two bridging phosphate groups. Its molecular formula is C21H27N7O14P2. The oxidized form is written NAD+ (an electron acceptor); the reduced form, which has accepted electrons and a hydrogen, is NADH (an electron donor). Together the NAD+/NADH couple is the primary redox workhorse in cellular energy metabolism.

NAD+ is endogenous — your body makes it from dietary precursors (tryptophan, nicotinic acid, nicotinamide, NMN, NR) via the salvage and de novo biosynthesis pathways. It is not a drug. It is sold as a dietary supplement in capsule form and, in some settings, as an intravenous infusion. Its schema.org type is DietarySupplement, not Drug.

NAD+ versus its precursors. A key distinction for reading the literature: oral NAD+ itself is not efficiently taken up intact by cells; the consensus view is that NMN and NR (both of which enter cells and are converted to NAD+ intracellularly) are the rational oral strategy for raising intracellular NAD+ levels. When this desk cites a study using NMN or NR, it says so explicitly — the precursors and NAD+ itself are not the same intervention.

How it works

NAD+'s biological functions fall into two broad categories.

Redox carrier. In glycolysis, the TCA cycle, and oxidative phosphorylation, NAD+ accepts electrons (becoming NADH), which are then passed to the mitochondrial electron transport chain to drive ATP synthesis. Without adequate NAD+, this central energy-generating pathway runs inefficiently.

Signaling substrate. Several families of enzymes consume NAD+ as they carry out their functions:

• Sirtuins (SIRT1–SIRT7): NAD+-dependent deacylases that remove acetyl groups from histones and other proteins, regulating gene expression, mitochondrial biogenesis, stress response, and inflammation. Sirtuin activity declines when NAD+ is low.
• PARPs (particularly PARP1): Poly(ADP-ribose) polymerases that use NAD+ to ADP-ribosylate proteins in response to DNA strand breaks. High PARP activity (during genomic stress) can rapidly deplete the local NAD+ pool.
• CD38/CD157: NAD-consuming ectoenzymes that rise with age and inflammation, partly explaining the age-associated decline in NAD+ ^[16].
• NAMPT (nicotinamide phosphoribosyltransferase): The rate-limiting enzyme in the NAD+ salvage pathway; its activity determines how efficiently the cell recycles NAD+ from nicotinamide.

Tissue NAD+ declines with age in multiple model organisms and in humans, and that decline is mechanistically linked to reduced sirtuin activity, impaired DNA repair, and metabolic dysfunction ^[16].

What the research shows

Foundational review (2021). A Nature Reviews Molecular Cell Biology analysis of NAD+ metabolism and aging across yeast, worms, mice, and humans established that declining NAD+ with age is linked to metabolic dysfunction and disease susceptibility ^[16]. It identified the three main consumer families — sirtuins, PARPs, CD38 — and framed NAD+ restoration as a candidate aging-biology strategy.

NMN in prediabetic women (2021). A Science paper (placebo-controlled, 10 weeks of oral NMN at 250 mg/day) found significantly improved muscle insulin sensitivity in prediabetic postmenopausal women, assessed by hyperinsulinemic-euglycemic clamp — a direct measure of insulin action in muscle. Body composition and HbA1c did not change ^[15]. This is one of the few well-controlled human mechanistic studies demonstrating a tissue-level metabolic effect of an NAD+ precursor.

Dose-response NR study (2019). In a randomized, double-blind, placebo-controlled study of 100–1000 mg/day of NR (nicotinamide riboside) over 8 weeks in healthy overweight adults, whole-blood NAD+ rose dose-dependently by approximately 22%, 51%, and 142% at the three doses ^[17]. NR did not elevate LDL cholesterol or disrupt one-carbon metabolism; no significant adverse events at any dose. This confirmed that oral NR is a well-tolerated, dose-scalable NAD+ booster at the blood level.

NMN dose-ranging multicenter RCT (2023). In a multicenter, double-blind, placebo-controlled, parallel-group trial of 300, 600, or 900 mg/day of NMN for 60 days in healthy middle-aged adults, blood NAD+ rose significantly versus placebo at both 30 and 60 days across all NMN groups (p≤0.001); walking distance and quality-of-life scores improved; 600 mg/day was identified as the optimal dose ^[14].

2025 Nature Metabolism review. The most current authoritative synthesis of the human clinical evidence concluded that human trials have shown limited efficacy in translating NAD+ blood elevation to clinical endpoints, that age-related NAD+ decline has been consistently observed only in a limited number of human studies, and that tissue-specific NAD+ dynamics remain sparse ^[13]. The review underscored the need for more human studies of systemic and tissue-specific NAD+ metabolism rather than continued extrapolation from rodent work.

Reported effects, cautions & safety

No peer-reviewed or aggregated community-anecdote data for NAD+ supplementation were compiled in this desk's source material; the entries below reflect documented uncertainties and cautions from the published literature.

Key uncertainties and cautions.

• Oral NAD+ absorption: Most researchers consider direct oral NAD+ an inefficient way to raise intracellular NAD+, because the intact molecule is not well absorbed. Precursors (NMN, NR) are considered the rational oral strategy. Some products sold as "NAD+" capsules may primarily deliver nicotinamide, which is converted to NAD+ via the salvage pathway.
• Blood elevation versus tissue and clinical endpoints: Raising blood NAD+ with precursors is well documented. Whether that reliably raises NAD+ in specific tissues (muscle, brain, liver) in humans, and whether that translates to clinical benefit, are much less established — the 2025 review is explicit on this point ^[13].
• Rodent-to-human translation gap: Much of the strongest longevity and anti-aging data comes from model organisms and may not extrapolate to humans. Human lifespans and metabolic rates differ from those of mice in ways that complicate dose extrapolation.
• IV NAD+ infusions: Marketed aggressively in wellness settings, IV NAD+ infusions rest on minimal controlled evidence. Infused NAD+ is rapidly cleared from plasma, and infusions can cause chest discomfort, abdominal cramping, flushing, and nausea if administered too quickly. A compounded injectable NAD+ product has been subject to a Class I FDA recall for elevated bacterial endotoxin.
• Cancer biology concern (theoretical): NAD+ supports energy metabolism in all proliferating cells, including malignant ones. NAD+ in oncology has dual, context-dependent roles — both protective (DNA repair) and potentially tumor-supportive. This is a theoretical concern flagged in the academic literature for cancer populations.
• NMN regulatory status: The FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was investigated as a new drug, creating marketplace uncertainty about its supplement status in the United States.
• Product quality: Supplement-grade NAD+ precursor products vary widely in actual content and purity; third-party testing is not guaranteed.

Where NAD+ fits in this desk

NAD+ sits in an unusual position on this desk: it is the most biochemically fundamental of the three entries — every cell in every organism depends on it — but it is also the one with the most modest translation to hard human clinical outcomes so far. Semaglutide has Phase 3 trials; MOTS-c has a mechanistically novel animal record; NAD+ has consistent evidence of precursor-driven blood elevation and some early mechanistic wins in muscle insulin sensitivity ^[15], but the clinical-endpoint story is still being written.

The connection to the metabolic-and-cellular-aging theme of this desk is direct: NAD+ is the common currency of the mitochondrial electron transport chain, the substrate for the sirtuins that MOTS-c activates indirectly through AMPK, and the cofactor for the DNA-repair enzymes whose decline tracks aging across species. Understanding it is part of understanding why the other two compounds are researched. See the comparison page for how all three line up.